Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs
Authors:
- Iole CordoneICIole Cordone
- Rachele AmodeoRARachele Amodeo
- Silvia BellesiSBSilvia Bellesi
- Fiorella BottanFBFiorella Bottan
- Francesco BuccisanoFrancesco Buccisano
- Maria Stefania De ProprisMPMaria Stefania De Propris
- Serena MasiSMSerena Masi
- Valentina PanichiVPValentina Panichi
- Maria Cristina ScerpaMSMaria Cristina Scerpa
- Ombretta AnnibaliOAOmbretta Annibali
- Velia BongarzoniVBVelia Bongarzoni
- Tommaso Caravita di TorittoTTTommaso Caravita di Toritto
Open Access
Abstract
Flow cytometry is a highly sensitive and specific approach for discriminating between normal and clonal plasma cells in multiple myeloma. Uniform response criteria after treatment have been established by the International Myeloma Working Group and the EuroFlow Group; however, the way in which flow cytometry data are reported has suffered from no collaborative or multicentre efforts. This study, involving 8 expert laboratories and 12 clinical hematology units of the Lazio region in Italy, aims to produce a uniform and shared report among the various Centres. From the pre-analytical phase to sample processing, data acquisition, analysis, and evaluation of the potential limitations and pitfalls of the entire process, the study reaches a final conclusion shared by laboratories and clinicians according to the most updated principles and recommendations. The aim was to identify the necessary data to be included in the clinical report by using multiple-choice questionnaires at every single stage of the process. An agreement of more than 75% of the laboratories was considered mandatory for the data to be included in the report. By ensuring the operational autonomy of each laboratory, this study provides a clear report that limits subjective interpretations and highlights possible bias in the process, better supporting clinical decision-making.Keywords
This publication has 59 references indexed in Scilit:
- Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reportingCytometry Part B: Clinical Cytometry, 2015
- Consensus guidelines for myeloma minimal residual disease sample staining and data acquisitionCytometry Part B: Clinical Cytometry, 2015
- Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agentsLeukemia & Lymphoma, 2014
- Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part V – assay performance criteriaCytometry Part B: Clinical Cytometry, 2013
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyJournal of Clinical Oncology, 2013
- Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratificationLeukemia, 2013
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis RevisitedAdvances in Hematology, 2012
- Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myelomaJournal of Clinical Pathology, 2012
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Blood, 2011